| 1 |
23867518 | Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics. | 2013 Jul-Aug |
1 |
| 2 |
22412884 | Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. | 2012 |
1 |
| 3 |
21627339 | Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis. | 2011 |
1 |
| 4 |
20545945 | Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation. | 2010 Aug |
1 |
| 5 |
21030045 | The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma. | 2010 Dec |
1 |
| 6 |
18525301 | Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma. | 2008 Jun |
1 |
| 7 |
18711190 | Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. | 2008 Aug 20 |
1 |